证券代码：002476 证券简称：宝莫股份 公告编号：2023-025 山东宝莫生物化工股份有限公司 关于召开公司 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年第一次临时股东大会。 2、股东大会召集人：公司第六届董事会。 根据山东宝莫生物化工股份有限公司（以下简称"公司"或"本公司"）于 2023 年 8 月 12 日召开的第六届董事会第八次会议，决定于 2023 年 8 月 31 日召 开 2023 年第一次临时股东大会（以下简称"本次股东大会"）。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件及《山东宝莫生物化工股份有限公司章程》的规定， 召集人资格及程序合法有效。 4、会议召开的日期、时间： （1） 现场会议召开时间：2023 年 8 月 31 日（星期四）下午 14:30。 （2） 网络投票时间：公司同时提供深圳证券交易所交易系统和互联网投票 系统供股东进行网络投票。 通过深圳证券交易所交易系统进行网络投票的具 ...

山东宝莫生物化工股份有限公司 独立董事关于第六届董事会第八次会议相关事项 所持目标公司的股权，如果目标公司未完成金矿增储工作，或原目标公司原实际 控制人发生属于严重损害目标公司及成都宝莫利益的违约行为且未在合理期限 内纠正，远期股权收购协议将丧失履约的前提条件，并且成都宝莫不会承担任何 违约责任。据此，我们认为，本次拟签署的远期股权收购协议并非使成都宝莫单 方负担了任何不合理义务，实际上是如果将来发生有利于进一步增强目标公司可 持续经营能力的变化时，成都宝莫有权进一步收购目标公司股权，体现义务履行 与享有利益相匹配的基本原则。该事项不会导致公司在现时状态下经济利益的流 出，不存在公司对关联方利益倾斜的情形，也不会影响公司现有业务的正常开展， 不存在损害公司股东及中小股东利益的情形。将来如果满足履行收购协议约定的 条件时，届时将严格按照规定履行相应的关联交易审议程序。 的事前认可意见 根据中国证监会《上市公司独立董事规则》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》及 《山东宝莫生物化工股份有限公司章程》等有关规定，作为公司第六届董事会的 独立董事， ...

山东宝莫生物化工股份有限公司 1、结合了解的有关信息并根据前期相关报告资料，本次拟交易事项定价遵 循了公正、公允、合理的基本原则，公司与目标公司及股权转让方不存在关联关 系，本次交易作价系在四川天健华衡资产评估有限公司所出具《评估报告》记载 的评估值基础上经各方协商确定，交易价格公允。本次拟交易事项决策程序规范， 不会影响公司现有业务的正常开展，不存在损害公司及股东特别是中小股东利益 的情形。本次拟交易事项完成后，公司将有能力控制目标公司的生产经营活动， 同时有利于最大限度降低非因不可控因素可能导致的投资风险，有利于改善公司 未来的经营状况，符合公司整体的发展战略目标。 独立董事关于第六届董事会第八次会议相关事项 的独立意见 根据中国证监会《上市公司独立董事规则》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》及 《山东宝莫生物化工股份有限公司章程》等有关规定，作为公司第六届董事会的 独立董事，本着认真、负责的态度，基于独立、审慎、客观的立场，对第六届董 事会第八次会议审议的相关事项进行了认真审核，并发表如下独立意见： 一、关于公司全资子公司拟签署股权 ...

证券代码：002476 证券简称：宝莫股份 公告编号：2023-024 山东宝莫生物化工股份有限公司 关于全资公司拟签署远期收购协议的公告 2023 年 8 月 12 日，山东宝莫生物化工股份有限公司（下称"公司"）第六 届董事会第八次会议审议通过了《关于全资子公司拟签署远期收购协议的议案》， 基于持续看好醴陵市日景矿业发展有限公司（下称"目标公司"）金矿业务未来 的发展，同意公司全资子公司成都宝莫矿业有限公司（下称"成都宝莫"）拟于 未来适当时候收购成都磐石矿业合伙企业（有限合伙）（下称"磐石矿业"）持有 的目标公司 9.0897%股权（对应出资额为 2,110.145528 万元），若磐石矿业持有 的目标公司股权比例后续发生变动的，成都宝莫拟收购的股权系指磐石矿业届时 持有的目标公司全部股权（以下简称"标的股权"）。 公司全体独立董事发表了同意的事前认可意见和独立意见，关联董事陶旭城 先生、熊锐新先生、王伟名先生、王姝怡女士回避表决，具体内容详见同日披露 在公司指定信息披露媒体巨潮资讯网（http://www.cninfo.com.cn）《第六届董 事会第八次会议决议的公告》、《独立董事关于公司第六届董事 ...

山东宝莫生物化工股份有限公司 关于全资子公司拟签署股权收购协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1.山东宝莫生物化工股份有限公司（下称"公司"）的全资子公司成都宝莫 矿业有限公司（下称"成都宝莫"）拟通过现金方式购买湖南众鑫实业发展有限 公司（下称"众鑫实业"）所持醴陵市日景矿业发展有限公司（下称"目标公司"） 36%的股权（下称"标的股权"），对应出资额为 8,357.2477 万元（下称"本次交 易"），交易完成后成都宝莫持有目标公司的股权比例变更为 52.41%，对应出资 额为 12,166.8193 万元，将成为目标公司的控股股东。 2.本次交易以四川天健华衡资产评估有限公司（下称"天健华衡"或"资产 评估机构"）出具的资产评估报告（评估报告编号：川华衡评报[2023]196 号）作 为定价依据。 证券代码：002476 证券简称：宝莫股份 公告编号：2023-022 3.本次交易构成关联交易，但不构成重大资产重组，交易实施不存在重大法 律障碍。 4.本次交易已经公司第六届董事会第八次会议审议通过，尚须获得公司股东 ...

山东宝莫生物化工股份有限公司 2023 年第一季度报告 证券代码：002476 证券简称：宝莫股份 公告编号：2023-012 山东宝莫生物化工股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 98,407,036.72 | 147,248,909.05 | -33.17% | | 归属于上市公司股东的净利 | -3,923,995.10 | 9,874,608.1 ...

Financial Performance - The company's operating revenue for 2022 was ¥592,284,770.21, a decrease of 9.87% compared to ¥657,160,020.80 in 2021[22]. - Net profit attributable to shareholders increased by 65.09% to ¥29,630,378.11 in 2022 from ¥17,948,109.83 in 2021[22]. - The basic earnings per share rose by 65.19% to ¥0.0484 in 2022, compared to ¥0.0293 in 2021[22]. - The total assets at the end of 2022 were ¥1,039,968,863.39, reflecting a 4.80% increase from ¥992,377,094.35 at the end of 2021[22]. - The company reported a significant cash flow deficit from operating activities of ¥78,171,438.21 in 2022, worsening by 124.57% from a deficit of ¥34,809,678.63 in 2021[22]. - The company reported a total of ¥4,549,508.02 in non-recurring gains in 2022, compared to ¥2,949,303.64 in 2021[28]. - The weighted average return on equity increased to 3.47% in 2022 from 2.16% in 2021[22]. - The company achieved operating revenue of ¥592,284,770.21, a decrease of 9.87% compared to the previous year[40]. - Total revenue for 2022 was ¥592,284,770.21, a decrease of 9.87% compared to ¥657,160,020.80 in 2021[44]. - The company reported a significant increase in revenue from commodity trading, which rose by 428.15% to ¥20,775,120.19[44]. - Domestic revenue decreased by 22.44% to ¥432,891,924.52, while international revenue increased by 61.00% to ¥159,392,845.69[44]. - The gross profit margin for chemical raw materials and chemical products manufacturing improved to 18.16%, up from 15.50% in the previous year[46]. - The company reported a total revenue of 1.5 billion in 2022, representing a year-over-year increase of 10%[99]. - The company reported a total revenue of 3.1 billion in 2022, maintaining a stable performance compared to previous years[100]. Market Strategy and Expansion - The company plans to enhance its market expansion strategy by increasing participation in international exhibitions and leveraging e-commerce platforms to penetrate markets in North America, the Middle East, and Southeast Asia[33]. - The company aims to strengthen its sales system and improve after-sales technical service capabilities to meet the strategic needs of oilfield development[33]. - The company is focusing on the development of shale oil and gas supporting products, including three types of oil reservoir development agents and offshore oil extraction agents[33]. - The company plans to continue optimizing product structure and enhancing service quality to address challenges in overseas markets[49]. - The company aims to enhance market expansion in oilfield products, focusing on surfactants and offshore oilfield additives, while also targeting water treatment and paper-making markets[84]. - The company is actively pursuing new business opportunities in the mining sector to enhance operational efficiency and profitability[85]. - The company will continue to explore sustainable development strategies and seek high-quality assets for long-term growth[85]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[99]. - Market expansion plans include entering three new international markets by the end of 2023[99]. Research and Development - The company is developing a high-salt-resistant fracturing fluid with low residue and better shear resistance, aiming to expand its product market in oil and gas extraction[60]. - The new biocatalyst application technology is expected to improve production efficiency and product quality while reducing production costs[60]. - The company is conducting industrial trials for a new type of emulsified temperature-resistant salt-reducing agent, which is anticipated to enhance product performance and market competitiveness[61]. - A dual-effect heavy oil viscosity reducer is being developed, with the goal of reducing interfacial tension and improving oil washing efficiency[60]. - The company is optimizing the catalytic reaction process for acrylamide production, which is expected to enhance product quality and reduce production costs[60]. - The development of a low molecular weight anionic drilling fluid flocculant is aimed at improving mechanical drilling speed and reducing drilling costs[61]. - The company is working on a new production process for low residual single-phase emulsion polymer, which is expected to meet industry requirements in water treatment and oil extraction[61]. - A new granulation technology is being researched to produce ultra-low molecular weight polyacrylamide, which will extend shelf life and reduce transportation costs[61]. - The company is focusing on synthesizing a high-stability acid-thickening agent that meets temperature and acid requirements for various geological conditions[61]. - R&D investment increased by 13.79% to ¥25,485,989.84, representing 4.30% of operating revenue, up from 3.41% in the previous year[62]. - The number of R&D personnel remained stable at 69, with a slight increase in the proportion of R&D staff to total employees from 14.08% to 14.62%[62]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[103]. - The management team emphasizes the importance of innovation in product development to meet evolving market demands[104]. - The company plans to invest in research and development to support the launch of new products in the next fiscal period[103]. Governance and Management - The company has maintained a focus on risk management in its derivative trading, ensuring compliance with internal controls and regulatory requirements[77]. - The company reported no fundraising activities during the reporting period[78]. - The company has established a comprehensive procurement, production, and sales system, ensuring autonomous market operations[96]. - The board of directors and supervisory board operate independently, with no interference from the controlling shareholder[96]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate reporting of significant information[94]. - The independent directors actively participate in decision-making, ensuring fairness and objectivity[92]. - The company has established specialized committees to promote standardized operations and sustainable development[92]. - The company has a diverse management team with backgrounds in finance, auditing, and risk management[107]. - The company is focused on enhancing its governance structure through the appointment of qualified independent directors and supervisors[106]. - The company has implemented a monthly payment system for director and supervisor allowances, with performance bonuses distributed based on assessments[109]. - The board of directors held a total of 8 meetings during the reporting period, with all members attending their respective meetings without any absences[112]. - The company maintained a structured approach to internal control management, enhancing operational quality and risk prevention measures[117]. - The company has adhered to the requirements of the China Securities Regulatory Commission regarding integrity in operations, with no reported violations[121]. - The internal audit process has been deemed effective in promoting the company's operational integrity and compliance[119]. Environmental and Social Responsibility - Environmental protection expenditures totaled CNY 1,108,827.43 during the reporting period[143]. - The wastewater treatment facility has a processing capacity of 1,500 cubic meters per day and operates normally[140]. - The company implemented a rainwater and sewage diversion system in March 2022 to reduce environmental and soil pollution[140]. - The company has a waste gas treatment system in place, including a condensation absorption device for the acrylonitrile storage tank[139]. - The company has established an emergency response plan for potential environmental incidents, which has been filed with the local environmental authority[141]. - The company has a wastewater treatment agreement with Sinopec for deep processing and compliant discharge[140]. - The company has installed a chemical washing and biological deodorization system at its wastewater treatment facility[139]. - The company has ceased operation of a 40-ton/hour coal-fired steam boiler, switching to centralized heating to reduce carbon emissions[143]. - The company did not face any administrative penalties related to environmental issues during the reporting period[144]. - The company conducted 18 safety inspections in 2022, identifying 137 hazards, all of which were rectified within the designated period[146]. - There were no major safety incidents reported during the year[147]. - The company has not engaged in poverty alleviation or rural revitalization efforts during the reporting period[148]. Shareholder and Equity Information - The company reported a total of 43,575 shareholders at the end of the reporting period[187]. - The largest shareholder, Tibet Taiyi Feng Information Technology Co., Ltd., holds 96,698,030 shares, representing 15.80% of total shares[188]. - The second-largest shareholder, Wu Hao, owns 34,145,176 shares, which is 5.58% of total shares[188]. - The total number of shares after the recent changes is 612,000,000, maintaining a 100% ownership structure[185]. - The number of restricted shares decreased by 2,325, resulting in a total of 49,050 restricted shares, which is 0.01% of total shares[184]. - The unlimited sale condition shares increased by 2,325, bringing the total to 611,950,625, which accounts for 99.99% of total shares[184]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[191]. - The audit report issued by the accounting firm indicates a standard unqualified opinion, confirming that the financial statements fairly reflect the company's financial position as of December 31, 2022[199]. - The company has not reported any significant changes in the shareholding structure or any pledges of shares by major shareholders[192]. - The company has not engaged in any repurchase transactions during the reporting period[192]. - There are no preferred shares or bond-related issues reported for the company during the period[194][197].

（问题征集专题页面二维码） 山东宝莫生物化工股份有限公司（以下简称"公司"）2022 年年度报告于 2023 年 4 月 20 日披露，为使广大投资者进一步了解公司 2022 年年度报告和经 营情况，公司定于 2023 年 4 月 25 日（星期二）下午 15:00—17:00 在深圳证券 信息有限公司提供的网上平台举行公司 2022 年度报告网上说明会。 本次说明会将采用网络远程方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次说明会。出席本次说明会的人员有：公司董事 长陶旭城先生，财务负责人（财务总监）王姝怡女士，副总经理、董事会秘书张 世鹏先生，独立董事童利忠先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 24 日（星期一）15：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面。 公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回答。欢 迎广大投资者积极参与本次网上说明会！ 证券代 ...

证券代码：002476 证券简称：宝莫股份 公告编号：2022-043 山东宝莫生物化工股份有限公司 关于参加山东辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，构建和谐投资者关系，山东宝莫生物化 工股份有限公司（以下简称"公司"）将参加由山东证监局联合协会等单位举办 的"山东辖区上市公司 2022 年度投资者网上集体接待日活动"，现将有关事项公 告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的网上平台举行， 广大投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与公 司互动交流，互动交流的时间为 2022 年 11 月 16 日（周三）14:00 - 16:00。 届时公司董事、财务负责人（财务总监）王姝怡女士以及副总经理、董事会 秘书张世鹏先生将通过网络在线互动的形式，与广大投资者就公司治理及社会责 任/ESG、经营状况、发展战略、风险防控、投资者保护、三季度报告等投资者关 心的问题进行交流。 欢迎广大投资者积极参与！ ...

山东宝莫生物化工股份有限公司 2022 年第三季度报告 证券代码：002476 证券简称：宝莫股份 公告编号：2022-041 1 山东宝莫生物化工股份有限公司 2022 年第三季度报告 山东宝莫生物化工股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 121,614,664.07 | -44. ...